APA

Reusch J., Stewart M. W., Perkins C. M., Cirkel D. T., Ye J., Perry C. R., Reinhardt R. R. & Bode B. W. (20150825). Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. : Diabetes, obesity & metabolism.

Chicago

Reusch J, Stewart M W, Perkins C M, Cirkel D T, Ye J, Perry C R, Reinhardt R R and Bode B W. 20150825. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. : Diabetes, obesity & metabolism.

Harvard

Reusch J., Stewart M. W., Perkins C. M., Cirkel D. T., Ye J., Perry C. R., Reinhardt R. R. and Bode B. W. (20150825). Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. : Diabetes, obesity & metabolism.

MLA

Reusch J, Stewart M W, Perkins C M, Cirkel D T, Ye J, Perry C R, Reinhardt R R and Bode B W. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. : Diabetes, obesity & metabolism. 20150825.